BioLife Solutions vs Haemonetics
Add, change or remove companies; up to four.
The short version
- Haemonetics is the larger business, with $1.3B of revenue in fiscal 2026 against $96.2M for BioLife Solutions, about 14 times as much.
- BioLife Solutions grew revenue faster (28.9%, against −2.0%).
- Haemonetics kept more of each dollar of sales as operating profit (11.8% operating margin, against −17.3%).
- Haemonetics turned more of its sales into free cash flow (19.5% FCF margin, against 11.1%).
- Haemonetics earned a higher return on the capital invested in it (6.7%, against −4.8%).
| Latest fiscal year | BLFS · FY25 | HAE · FY26 |
|---|---|---|
| Size | ||
| Market cap | — | $5.4B |
| Revenue | $96.2M | $1.3B |
| Free cash flow | $10.6M | $260M |
| Net income | −$4.6M | $97.3M |
| Growth | ||
| Revenue growth | 28.9% | −2.0% |
| 5-year growth | 14.9% | 8.9% |
| Share count change | 5.6% | −6.7% |
| Profitability | ||
| Gross margin | 64.6% | 59.0% |
| Operating margin | −17.3% | 11.8% |
| Net margin | −4.8% | 7.3% |
| FCF margin | 11.1% | 19.5% |
| Return on capital | −4.8% | 6.7% |
| Return on equity | −1.3% | 12.0% |
| Balance sheet | ||
| Net debt | −$83.9M | $994M |
| Net debt / EBITDA | — | 3.7x |
| Dividends and buybacks | $0.0M | $175M |
| Valuation & quality | ||
| P/E | — | 57.3x |
| Piotroski F-score | 6 | 7 |
Revenue
FY17
BLFS $11.0M
HAE $886M
FY18
BLFS $19.7M
HAE $904M
FY19
BLFS $27.4M
HAE $968M
FY20
BLFS $48.1M
HAE $989M
FY21
BLFS $119M
HAE $871M
FY22
BLFS $76.2M
HAE $993M
FY23
BLFS $68.0M
HAE $1.2B
FY24
BLFS $74.6M
HAE $1.3B
FY25
BLFS $96.2M
HAE $1.4B
FY26
BLFS —
HAE $1.3B
BLFS
HAE
Operating margin
FY17
BLFS −9.6%
HAE −2.2%
FY18
BLFS 18.6%
HAE 6.2%
FY19
BLFS −0.8%
HAE 8.6%
FY20
BLFS −13.0%
HAE 10.5%
FY21
BLFS −29.5%
HAE 10.3%
FY22
BLFS −7.8%
HAE 8.1%
FY23
BLFS −25.3%
HAE 13.4%
FY24
BLFS −6.0%
HAE 12.6%
FY25
BLFS −17.3%
HAE 16.3%
FY26
BLFS —
HAE 11.8%
BLFS
HAE
Free cash flow
FY17
BLFS $0.5M
HAE $83.6M
FY18
BLFS $1.9M
HAE $146M
FY19
BLFS $0.5M
HAE $40.3M
FY20
BLFS $4.7M
HAE $109M
FY21
BLFS −$13.0M
HAE $71.8M
FY22
BLFS −$18.9M
HAE $75.8M
FY23
BLFS −$18.9M
HAE $81.7M
FY24
BLFS $5.2M
HAE $144M
FY25
BLFS $10.6M
HAE $142M
FY26
BLFS —
HAE $260M
BLFS
HAE
Return on capital
FY17
BLFS —
HAE −1.6%
FY18
BLFS —
HAE 4.9%
FY19
BLFS —
HAE 7.5%
FY20
BLFS −6.5%
HAE 10.8%
FY21
BLFS −10.5%
HAE 8.6%
FY22
BLFS −1.3%
HAE 4.4%
FY23
BLFS −4.2%
HAE 9.9%
FY24
BLFS −1.2%
HAE 8.8%
FY25
BLFS −4.8%
HAE 10.5%
FY26
BLFS —
HAE 6.7%
BLFS
HAE
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.